Midorikawa Y - Search Results

1

Genomic approach towards personalized anticancer drug therapy.

Midorikawa Y, Tsuji S, Takayama T, Aburatani H. Midorikawa Y, et al. Pharmacogenomics. 2012 Jan;13(2):191-9. doi: 10.2217/pgs.11.157. Pharmacogenomics. 2012. PMID: 22256868 Review.

2

Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis.

Midorikawa Y, Tsutsumi S, Taniguchi H, Ishii M, Kobune Y, Kodama T, Makuuchi M, Aburatani H. Midorikawa Y, et al. Jpn J Cancer Res. 2002 Jun;93(6):636-43. doi: 10.1111/j.1349-7006.2002.tb01301.x. Jpn J Cancer Res. 2002. PMID: 12079511 Free PMC article.

3

Development of well-differentiated hepatocellular carcinoma in large adenomatous hyperplasia after long-term follow-up: a case report.

Midorikawa Y, Ishikawa T, Kubota K, Mori M, Takayama T, Makuuchi M. Midorikawa Y, et al. Hepatogastroenterology. 2002 Jul-Aug;49(46):1098-101. Hepatogastroenterology. 2002. PMID: 12143212

4

Hepatocellular carcinoma originating from intramural cells in the bile duct.

Hasegawa K, Kubota K, Mori M, Midorikawa Y, Takayama T, Makuuchi M. Hasegawa K, et al. Among authors: midorikawa y. Hepatogastroenterology. 2002 Nov-Dec;49(48):1688-91. Hepatogastroenterology. 2002. PMID: 12397767

5

Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling.

Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M, Aburatani H. Midorikawa Y, et al. Int J Cancer. 2003 Feb 10;103(4):455-65. doi: 10.1002/ijc.10856. Int J Cancer. 2003. PMID: 12478660

6

Extended right hepatectomy and total gastrectomy with double Roux-en-Y reconstruction for hilar bile duct and gastric carcinomas.

Hasegawa K, Kubota K, Midorikawa Y, Matsui Y, Mafune K, Takayama T, Makuuchi M. Hasegawa K, et al. Among authors: midorikawa y. Hepatogastroenterology. 2003 Mar-Apr;50(50):374-6. Hepatogastroenterology. 2003. PMID: 12749225

7

Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma.

Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo T, Kodama T, Aburatani H. Hippo Y, et al. Among authors: midorikawa y. Cancer Res. 2004 Apr 1;64(7):2418-23. doi: 10.1158/0008-5472.can-03-2191. Cancer Res. 2004. PMID: 15059894

8

Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma.

Midorikawa Y, Tsutsumi S, Nishimura K, Kamimura N, Kano M, Sakamoto H, Makuuchi M, Aburatani H. Midorikawa Y, et al. Cancer Res. 2004 Oct 15;64(20):7263-70. doi: 10.1158/0008-5472.CAN-04-1275. Cancer Res. 2004. PMID: 15492245

9

The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.

Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M. Yamauchi N, et al. Among authors: midorikawa y. Mod Pathol. 2005 Dec;18(12):1591-8. doi: 10.1038/modpathol.3800436. Mod Pathol. 2005. PMID: 15920546 Free article.

10

Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues.

Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, Wang SM, Aburatani H. Ge X, et al. Among authors: midorikawa y. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008. Genomics. 2005. PMID: 15950434

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

203 results

Search Page

Filters